A Phase III, double-blind, randomised, placebo-controlled, international study to assess the efficacy and safety of adjuvant Osimertinib versus Placebo in participants with EGFR mutation-positive stage IA2-IA3 Non-small Cell Lung Cancer, following Complete tumour resection (ADAURA2)

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today